Emibetuzumab

Product Name: Emibetuzumab
CAS No.: 1365287-97-3
Chemical Name: Emibetuzumab
Synonyms: LY2875358;Emibetuzumab;Emibetuzumab (anti-MET);Research Grade Emibetuzumab;Research Grade Emibetuzumab(DHC34201)
CBNumber: CB28080907
Formula Weight: 0
MOL File: Mol file

More

Less

Emibetuzumab Property

form: Liquid
color: Colorless to light yellow

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

Emibetuzumab Chemical Properties,Usage,Production

Description

Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction, leading to MET internalization and degradation.

Uses

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1].

Clinical Use

A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.

in vivo

Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice^[1].
Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice^[1].
Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models^[1].

Animal Model:	Athymic nude mice (U87MG tumor xenograft model)^[1].
Dosage:	10 mg/kg
Administration:	Intravenous injection, once a week for 5 weeks.
Result:	Demonstrated a significant inhibition of tumor growth.

Animal Model:	Athymic nude mice (MKN45 xenograft tumor model)^[1].
Dosage:	10 or 20 mg/kg
Administration:	Intravenous injection, single.
Result:	Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.

Animal Model:	Athymic nude mice (MET-amplified xenograft mouse tumor models)^[1].
Dosage:	10 mg/kg
Administration:	Intravenous injection, once a week for 3, 5 or 6 weeks.
Result:	Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.

References

[1] Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. DOI:10.1158/1078-0432.CCR-14-0543

Emibetuzumab Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Emibetuzumab Suppliers

China 19 United States 1 Global 20

Shanghai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847; 18021002903
Fax: QQ:3008007432
Email: 3008007409@qq.com
Country: China
ProdList: 71826
Advantage: 60

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

Guangzhou Hongyuan Chemical Co.,Ltd

Tel: 15817493340
Email: 981810490@qq.com
Country: China
ProdList: 1566
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10308
Advantage: 58

TargetMol Chemicals Inc.

Tel: 4008200310
Email: marketing@tsbiochem.com
Country: China
ProdList: 24961
Advantage: 58

Biolab Reagents

Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Country: China
ProdList: 9868
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 6762
Advantage: 58

Shanghai Yifei Biotechnology Co. , Ltd.

Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Country: China
ProdList: 11973
Advantage: 58

Shanghai Aladdin Biochemical Technology Co.,Ltd.

Tel: 400-6206333 13167063860
Email: anhua.mao@aladdin-e.com
Country: China
ProdList: 48457
Advantage: 58

Changsha Fuzhen Biotechnology Co.，LTD

Tel: 0731-13823398 15111215862
Email: 313359644@qq.com
Country: China
ProdList: 4161
Advantage: 58

Wanxin Biotechnology (Jiaxing) Co., LTD

Tel: 0573-83568680 18057391398
Email: 3956524501@qq.com
Country: China
ProdList: 1442
Advantage: 58

Atagenix Laboratories

Tel: 027-87008169 17762441161
Email: info@atagenix.com
Country: China
ProdList: 10001
Advantage: 58

Sangon Biotech (Shanghai) Co.,Ltd.

Tel: 400-821-026
Email: Sales@sangon.com
Country: China
ProdList: 6710
Advantage: 58

AntibodySystem Laboratories SAS

Tel: 33175446423
Email: support@antibodysystem.com
Country: China
ProdList: 6739
Advantage: 58

Biosynth Biological Technology (Suzhou) Co Ltd

Tel: 51288865780
Email: sales@biosynth.com
Country: China
ProdList: 6051
Advantage: 58

Cell Sciences

Tel: 9785721070
Email: info@cellsciences.com
Country: China
ProdList: 6308
Advantage: 58

Guangzhou Chuangze Biotechnology Co., Ltd.

Tel: 18312220236
Country: CHINA
ProdList: 178
Advantage: 58

Shenzhen Campbell Biotechnology Co., Ltd.

Tel: 18028747627
Country: CHINA
ProdList: 191
Advantage: 58

Proteintech China

Tel: --
Fax: --
Email: Proteintech-CN@ptglab.com
Country: CHINA
ProdList: 6290
Advantage: 58

1365287-97-3, EmibetuzumabRelated Search:

Ustekinumab Secukinumab Etokimab nimotuzumab Tigatuzumab Elezanumab Mapatumumab Eptinezumab Vedolizumab Oportuzumab Monatox

Emibetuzumab

Research Grade Emibetuzumab(DHC34201)

Emibetuzumab (anti-MET)

LY2875358

Research Grade Emibetuzumab

1365287-97-3